NWRN.SW
NWRN.SW
IT0004147952
NEWRON PHARMA N
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 65/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±77.3% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.8x).

Beta (Market Relation)
0.85x
Defensive
Volatility (5Y p.a.)
77.3% p.a.
5-Year Horizon
Max Drawdown (5Y)
-76.3%
5-Year Horizon
Sharpe Ratio
0.35
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -53.1%
3 Years 66.9% -76.3% 0.06 +6.8%
5 Years 77.3% -76.3% 0.35 +29.2%
10 Years 72.3% -96.0% -0.17 -9.9%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (77.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -96.0% in the extended horizon.
ende